All In Biotech

Drug Trial Radar · NCT04307186

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Multicenter, Single-blind, Adaptive Dose Finding Study of Single Intravenous Injections of BAY 1747846 With Corresponding Blinded Read in Adult Participants With Known or Highly Suspected CNS Lesions Referred for Contrast-enhanced MRI of the CNS

Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

57

Actual

Start

Nov 18, 2020

Primary completion

Sep 5, 2022

Study completion Sep 6, 2022

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Mar 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers in this study want to find the appropriate dose of drug BAY1747846 for adults undergoing MRI for known or highly suspected brain and/or spinal cord conditions so that the image quality is similar to that of drug gadobutrol for adults undergoing MRI. MRI stands for Magnetic resonance imaging which produces body pictures created by using magnetic energy rather than x-ray energy. Both BAY1747846 and gadobutrol are medicinal products known as gadolinium-based contrast agents (GBCA) which are used in MRI examinations to provide contrast enhancement and improve imaging performance. Gadobutrol (brand name: Gadavist, Gadovist) has been approved worldwide for the diagnosis of various disorders in adult and pediatric patients. BAY1747846 is a new GBCA under development with the goal to provide similar imaging performances in MRI. Participants in this study will receive both BAY1747846 and gadobutrol with a period of 3 - 14 days in between. A MRI examination will be performed after each injection. Participant will stay in this study for 2 - 4 weeks depending on the scheduling of the visits.

Conditions

  • Central Nervous System Pathology

Interventions

  • Gadoquatrane (BAY1747846)Drug

    Solution for IV injection, single dose

  • Gadobutrol (Gadovist/Gadavist)Drug

    Solution for IV injection, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Diagnostic PreferenceTime frame: At 5 minute post each injection

Locations

17 sites in 4 countries. Site status is shown where the registry gives one.

  • Northwestern University

    Chicago, Illinois

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • UMHAT Sveti Georgi

    Plovdiv, Bulgaria

  • Acibadem City Clinic Multiprofile Hospital for Active Treatm

    Sofia, Bulgaria

  • University Multiprofile Hosp. for Active Treat. Sveti Ivan

    Sofia, Bulgaria

  • MVZ Prof. Uhlenbrock und Partner

    Dortmund, North Rhine-Westphalia, Germany

  • Universitätsklinikum Essen

    Essen, North Rhine-Westphalia, Germany

  • Friedrich-Schiller-Uni. Jena

    Jena, Thuringia, Germany

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Japan

  • Social Medical Corporation the Chiyukai foundation Fukuoka Wajiro Hospital

    Fukuoka, Japan

  • Hiroshima City Hiroshima Citizens Hospital

    Hiroshima, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • National Hospital Organization Himeji Medical Center

    Himeji, Hyōgo, Japan

  • Hyogo Prefectural Nishinomiya Hospital

    Nishinomiya, Hyōgo, Japan

  • Kishiwada Tokushukai Hospital

    Kishiwada, Osaka, Japan

  • National Hospital Organization Kanmon Medical Center

    Shimonoseki, Yamaguchi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.